Skip to main content
S&P 5007,718.60-0.38%DOW53,414.25-0.51%NASDAQ26,506.99-0.29%BTC$79,656.00-1.71%ETH$2,454.45-1.99%GOLD$4,477.20-1.38%OIL$91.22-0.09%
Smart Investors Daily
SG

OTC · SGIOY

Shionogi & Co., Ltd.

Healthcare · Drug Manufacturers - Specialty & Generic

$9.25

Down-$0.27 (-2.84%)

Updated Sep 6, 2026, 12:57 AM

SID Score

6.3/10

Composite research score

Smart Money

46/100

Neutral

Market cap
14.53B
P/E ratio
13.35
Dividend yield
2.18%
52-week range
— – —
Volume
6.45K
Avg. volume
100.96K

Price performance

SGIOY price history

1M range · 0 trading sessions · Daily adjusted prices

SGIOY does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest SGIOY news

The latest Smart Investors Daily articles mentioning SGIOY.

Stock researchCompany · Overview

SGIOY research

Overview

Company profile and research snapshot.

Company profile

SHIONOGI & CO UNSP/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 28, 2026

Shionogi Announces U.S. Government Procurement of Fetroja® (cefiderocol) Through BARDA's Project BioShield to Support National Preparedness for Drug-Resistant Bacterial Threats

OSAKA, Japan, August 28, 2026--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that the Biomedical Advanced Research and Development Authority (BARDA) has exercised a $36.9 million procurement option, under Project BioShield funding, from its April 2026 contract with Shionogi Inc., a New Jersey-based subsidiary of Shionogi, to procure Fetroja® (cefiderocol) as a critical countermeasure against difficult-to-treat Gra

Yahoo · Jul 30, 2026

Shionogi Recognizes the Four-Year Anniversary of RADICAVA ORS® (edaravone) for Treatment of ALS

FLORHAM PARK, N.J., July 30, 2026--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter, "Shionogi") today announced the four-year anniversary of RADICAVA ORS® (edaravone), the only oral formulation of edaravone approved by the U.S. Food and Drug Administration (FDA) for the treatment of amyotrophic lateral sclerosis (ALS).

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By